Stimulant Eye Drops for Asthenopia Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for asthenopia, or eye fatigue, such as OTC artificial tears, only provide limited relief, and there is a lack of topical ophthalmic drugs that utilize stimulants to effectively address this prevalent condition.
Innovation Solution
Development of ophthalmic compositions containing a therapeutically effective amount of one or more stimulants, such as caffeine, combined with non-essential amino acids and cooling agents, to be administered topically as eye drops for treating asthenopia and other eye-related issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If OTC artificial tears with viscosity enhancing agents are used to treat eye fatigue, then lubrication is provided and some symptoms are alleviated, but the treatment effect is limited and not dramatic enough
Solution Approach 1:
The patent combines multiple active ingredients (caffeine as stimulant, amino acids for nutrition, and viscosity enhancing agents for lubrication) into a composite ophthalmic formulation. This composite approach allows the solution to simultaneously address multiple aspects of eye fatigue through different mechanisms, achieving dramatic improvement without requiring overly complex delivery systems
Solution Approach 2:
The invention merges three distinct therapeutic approaches (stimulation, nutrition, and lubrication) into a single eye drop formulation. By combining caffeine, amino acids, and viscosity enhancing agents in one composition, the patent achieves synergistic effects that provide dramatic relief from eye fatigue while maintaining ease of administration
2Reliability
If topical ophthalmic drugs with stimulants are used to treat asthenopia, then brain activity promotion and awakeness increase, but no such drug currently exists with this unique combination
Solution Approach 1:
The patent creates a multi-functional ophthalmic drug that simultaneously provides stimulation (caffeine), nutrition (amino acids), and lubrication (viscosity enhancing agents). This universal formulation addresses multiple causes and symptoms of eye fatigue in a single product, making it broadly applicable to various cases of asthenopia while filling the market gap for stimulant-based eye drops
3Ease of operation
If current OTC artificial tears are used, then some symptom relief is achieved, but dramatic improvement on this prevalent condition is not attained
Solution Approach 1:
The patent changes the chemical parameters of the eye drop formulation by introducing caffeine and amino acids alongside traditional viscosity enhancing agents. This parameter change transforms the formulation from a simple lubricant into a multi-action therapy that provides both immediate comfort and sustained therapeutic benefit, achieving dramatic improvement while maintaining ease of use
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ophthalmic compositions effectively alleviate symptoms of asthenopia, including eye fatigue and discomfort, by providing a combination of stimulation, lubrication, and cooling, thereby improving eye health and reducing discomfort.
Implementation Method 1
Stimulants work by promoting brain activity and when ingested, can increase a sense of awakeness and energy. It has presently been studied that the topical use of an ophthalmic drug consisting of a stimulant, such as caffeine, can prove to have a similar effect when applied to the eyes
Implementation Method 2
The present treatment for this affliction is often over the counter ('OTC') artificial tears, wherein the mode of lubrication is through the use of viscosity enhancing agents or emulsions
Data Source
AI summary
An ophthalmic composition for tired eye therapy comprising effective amounts of at least one or more stimulants, one or more non-essential amino acids, or one or more cooling agents. Additional compounds for the ophthalmic composition as well as methods of making and using the ophthalmic compositions are further disclosed.